INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) announced that its drug EBGLYSS, an interleukin-13 (IL-13) inhibitor, has shown to improve skin condition and reduce... ByInvesting.com • 25 Oct ...

Credit: Getty Images The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products. Below is a review of novel drug and biological products ...

This page features the latest news about the Eli Lilly DRC share. Eli Lilly & Co. Reports EBGLYSS demonstrated meaningful improvement in skin clearance and itch relief in the majority of patients with ...

With this approval, HYQVIA [Immune Globulin Infusion 10% (human) with Recombinant Human Hyaluronidase] becomes the first and only facilitated subcutaneous immunoglobulin available in Japan to treat ...

In September 2024, the US Food and Drug Administration (FDA) approved Ebglyss (lebrikizumab-lbkz; Eli Lilly and Company), an interleukin (IL)-13 antagonist, for the treatment of moderate to severe ...

The drugmaker has received... INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) announced that its drug EBGLYSS, an interleukin-13 (IL-13) inhibitor, has shown to improve skin condition and ...

This guidance is underpinned by several growth drivers including new product launches such as Jaypirca, Ebglyss, Omvoh and Kisunla; additional indications for existing medicines; and further ...

Last September, the FDA approved Ebglyss for the treatment of eczema. With less frequent dosing, Ebglyss is expected to compete fiercely with Dupixent, a treatment that racked up over $13 billion ...

The company is also focusing on diversification with new products like Jaypirca, Omvoh, Ebglyss, and Kisunla, which could provide additional revenue streams and reduce dependence on any single ...